In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

AstraZeneca said on Monday its experimental weight-loss pill, licensed from China's Eccogene, was safe and tolerable in an ...

The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004, was well tolerated by patients in an early-stage ...

AstraZeneca Plc said its experimental obesity pill was well-tolerated by patients with type-2 diabetes as it presented data from several studies testing its three new weight-loss medicines.

Effectiveness and safety data from Viking’s study, released Sunday at an industry conference, show that an obesity pill could ...

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.

Obesity pill data released by Viking Therapeutics Inc and AstraZeneca Plc at a big conference foreshadowed an increasingly ...

When AstraZeneca announced it had licensed the experimental, once-daily obesity pill from Eccogene a year ago for up to $2 ...

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Shares of Viking Therapeutics (NASDAQ:VKTX) jumped 22% Monday morning after the biotech firm reported promising results for ...

Viking Therapeutics announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

AstraZeneca said its experimental weight loss pill was well tolerated by patients in an early-stage clinical trial. The Anglo-Swedish drugmaker’s closely watched weight loss pill, AZD5004 ...